Location History:
- Bottmingen, CH (1980)
- Pratteln, CH (1981 - 2011)
Company Filing History:
7 out of 3,923 
3 out of 6,850 
1 out of 595 
Years Active: 1980-2011
Title: Robert Portmann: A Pioneer in Pharmaceutical Innovations
Introduction
Robert Portmann is an accomplished inventor located in Pratteln, Switzerland. With a remarkable portfolio of 11 patents, Portmann has made significant contributions to the field of pharmaceuticals, particularly through his work on novel crystal modifications of pharmaceutical compounds.
Latest Patents
Among his latest patents, Portmann has developed the crystal modification A of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, along with various dosage forms and formulations. This invention pertains to dosage forms that include the crystal modification A, characterized by distinctive X-ray powder pattern lines with interplanar spacings (d values) ranging from 10.5 Å to 2.81 Å. These dosage forms can be administered orally or parenterally, available in both solid and liquid forms with dosages ranging from 20 mg to less than 500 mg. The solid dosage forms, such as tablets or capsules, incorporate a pharmaceutically-acceptable carrier and film-coat. Furthermore, Robert has also unveiled crystal modifications B and C of the same compound, focusing on their use and pharmaceutical preparations.
Career Highlights
Throughout his career, Portmann has been associated with several prominent companies in the pharmaceutical sector, including Novartis AG and Ciba-Geigy Corporation. His expertise and innovative mindset have positioned him as a leading figure in pharmaceutical research and development.
Collaborations
Portmann has collaborated with notable colleagues such as Walter Scherrer and Urs Christoph Hofmeier. Their collective efforts in research and innovation have contributed to advancing the understanding and application of pharmaceutical compounds.
Conclusion
Robert Portmann's dedication to innovation in the pharmaceutical industry is evident through his patents and collaborative efforts. His work continues to influence the development of new therapeutic methods, reflecting his commitment to enhancing healthcare outcomes.